JP2022515331A5 - - Google Patents

Info

Publication number
JP2022515331A5
JP2022515331A5 JP2021531836A JP2021531836A JP2022515331A5 JP 2022515331 A5 JP2022515331 A5 JP 2022515331A5 JP 2021531836 A JP2021531836 A JP 2021531836A JP 2021531836 A JP2021531836 A JP 2021531836A JP 2022515331 A5 JP2022515331 A5 JP 2022515331A5
Authority
JP
Japan
Prior art keywords
polypeptide
amino acid
hla
acid sequence
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021531836A
Other languages
English (en)
Japanese (ja)
Other versions
JP7481342B2 (ja
JP2022515331A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/067280 external-priority patent/WO2020132138A1/en
Publication of JP2022515331A publication Critical patent/JP2022515331A/ja
Publication of JP2022515331A5 publication Critical patent/JP2022515331A5/ja
Priority to JP2024070994A priority Critical patent/JP2024105344A/ja
Application granted granted Critical
Publication of JP7481342B2 publication Critical patent/JP7481342B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021531836A 2018-12-19 2019-12-18 多量体t細胞調節ポリペプチド及びその使用方法 Active JP7481342B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024070994A JP2024105344A (ja) 2018-12-19 2024-04-25 多量体t細胞調節ポリペプチド及びその使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862782205P 2018-12-19 2018-12-19
US62/782,205 2018-12-19
US201962814707P 2019-03-06 2019-03-06
US62/814,707 2019-03-06
PCT/US2019/067280 WO2020132138A1 (en) 2018-12-19 2019-12-18 Multimeric t-cell modulatory polypeptides and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024070994A Division JP2024105344A (ja) 2018-12-19 2024-04-25 多量体t細胞調節ポリペプチド及びその使用方法

Publications (3)

Publication Number Publication Date
JP2022515331A JP2022515331A (ja) 2022-02-18
JP2022515331A5 true JP2022515331A5 (enExample) 2022-12-26
JP7481342B2 JP7481342B2 (ja) 2024-05-10

Family

ID=71100346

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021531836A Active JP7481342B2 (ja) 2018-12-19 2019-12-18 多量体t細胞調節ポリペプチド及びその使用方法
JP2024070994A Pending JP2024105344A (ja) 2018-12-19 2024-04-25 多量体t細胞調節ポリペプチド及びその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024070994A Pending JP2024105344A (ja) 2018-12-19 2024-04-25 多量体t細胞調節ポリペプチド及びその使用方法

Country Status (12)

Country Link
US (2) US20220389079A1 (enExample)
EP (1) EP3897746A4 (enExample)
JP (2) JP7481342B2 (enExample)
KR (1) KR20210104700A (enExample)
CN (1) CN113286621A (enExample)
AU (1) AU2019401183A1 (enExample)
BR (1) BR112021011838A2 (enExample)
CA (1) CA3113096A1 (enExample)
IL (1) IL282250A (enExample)
MX (1) MX2021007479A (enExample)
TW (1) TWI856048B (enExample)
WO (1) WO2020132138A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2973548T3 (es) 2016-12-22 2024-06-20 Cue Biopharma Inc Polipéptidos multiméricos moduladores de linfocitos T y métodos para su uso
US20200010528A1 (en) 2017-03-15 2020-01-09 Cue Biopharma, Inc. Methods for modulating an immune response
JP2020534352A (ja) 2017-09-07 2020-11-26 キュー バイオファーマ,インコーポレーテッド コンジュゲーション部位を有するt細胞調節多量体ポリペプチド及びその使用方法
MX2021007479A (es) * 2018-12-19 2021-09-23 Cue Biopharma Inc Polipeptidos multimericos moduladores de linfocitos t y metodos de uso de estos.
WO2021127487A2 (en) 2019-12-20 2021-06-24 Regeneron Pharmaceuticals, Inc. Novel il2 agonists and methods of use thereof
WO2021231376A2 (en) 2020-05-12 2021-11-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
EP4210736A4 (en) * 2020-09-09 2024-10-23 Cue Biopharma, Inc. MULTIMERIC POLYPEPTIDES MODULATING MHC CLASS II T CELLS AND METHODS OF USE THEREOF
WO2022056014A1 (en) * 2020-09-09 2022-03-17 Cue Biopharma, Inc. Mhc class ii t-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof
TW202317623A (zh) 2021-06-14 2023-05-01 美商再生元醫藥公司 基於il2之治療劑及其使用方法
US20260097105A1 (en) * 2022-09-30 2026-04-09 The Children's Hospital Of Philadelphia Systems, formulations and methods for generating universal peptide/mhc complexes with engineered disulfide connecting the heavy and light chains

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015195531A2 (en) * 2014-06-18 2015-12-23 Albert Einstein College Of Medicine, Inc. Syntac polypeptides and uses thereof
DK3186283T3 (da) * 2014-08-29 2020-03-02 Hoffmann La Roche Kombinationsbehandling med tumormålrettede IL-2- immuncytokinervarianter og antistoffer mod humant PD-L1
EP3322715B1 (en) * 2015-07-14 2023-10-18 BioNTech SE Peptide mimotopes of the cd3 t-cell co-receptor epsilon chain and uses thereof
WO2017201210A1 (en) * 2016-05-18 2017-11-23 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
ES2973548T3 (es) * 2016-12-22 2024-06-20 Cue Biopharma Inc Polipéptidos multiméricos moduladores de linfocitos T y métodos para su uso
MX2021007479A (es) * 2018-12-19 2021-09-23 Cue Biopharma Inc Polipeptidos multimericos moduladores de linfocitos t y metodos de uso de estos.
KR20220015382A (ko) * 2019-05-29 2022-02-08 큐 바이오파마, 인크. 다량체 t-세포 조절 폴리펩타이드 및 이의 사용 방법
JP2022536581A (ja) * 2019-06-19 2022-08-18 キュー バイオファーマ, インコーポレイテッド 多量体t細胞調節性ポリペプチド及びその使用方法
CA3146917A1 (en) * 2019-10-23 2021-04-29 Anish SURI T-cell modulatory chimeric molecules and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2022515331A5 (enExample)
JP2020533273A5 (enExample)
JP2022534846A5 (enExample)
IL272085B (en) Multimeric t-cell modulatory polypeptides and methods of use thereof
KR102488477B1 (ko) 신속하고 포괄적인 t-세포 면역 모니터링을 위한 세포 플랫폼
AU2013295652B2 (en) Engineering T-cell receptors
JP2021500855A5 (enExample)
JP2020514375A5 (enExample)
KR102528977B1 (ko) 펩타이드-hla 복합체 및 그 제조 방법
JP2021500855A (ja) 抗原提示ポリペプチドおよびその使用方法
JP2020511136A5 (enExample)
JP7481342B2 (ja) 多量体t細胞調節ポリペプチド及びその使用方法
JP2022515330A5 (enExample)
JP2022536581A5 (enExample)
JP2018525006A5 (enExample)
US20250283037A1 (en) Methods for stimulating and transducing t cells
JP2023500574A5 (enExample)
JP2023526723A5 (enExample)
JP2021532742A5 (enExample)
Liang et al. A single TCRα-chain with dominant peptide recognition in the allorestricted HER2/neu-specific T cell repertoire
Clement et al. Anti-CD8 antibodies can trigger CD8+ T cell effector function in the absence of TCR engagement and improve peptide–MHCI tetramer staining
CA3201767A1 (en) Compositions and methods for cellular immunotherapy
Zhang et al. The effect of adjuvanting cancer vaccines with herpes simplex virus glycoprotein D on melanoma-driven CD8+ T cell exhaustion
CN112105650A (zh) 一种嵌合单链分子及其应用
US20220227883A1 (en) Immunotherapy constructs targeting kras antigens